Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

Inclusion Criteria

• •Acute myelogenous leukemia(AML) in first or subsequent remission, in untreated first relapse or any treated relapse.
• •Acute lymphoblastic leukemia(ALL) in first or subsequent remission, in untreated first relapse or any treated relapse.
• •Chronic myelogenous leukemia in first or second chronic stable phase or in accelerated phase.
• •Myelodysplastic syndromes or myeloproliferative diseases
• •Non-Hodgkin's lymphoma or Hodgkin's disease in second or greater complete remission, in partial remission, or induction failure.
• •Chronic lymphocytic leukemia, Rai stage 2-4, which has progressed after initial therapy.
• •Matched unrelated donor.
• •Age 18-55 years at the time of stem cell transplantation
• •ECOG performance status 0-2
• •Life expectancy of 100 days without stem cell transplantation
• •Total bilirubin \< 2.0 mg/dl
• •AST \< 90 IU
• •Serum creatinine \< 2.0 mg/dl
• •Ejection fraction \> 40% by echocardiogram or gated nuclear medicine study.